Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Journal of Managed Care & Specialty Pharmacy
|
May 28, 2016
Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets
Elizabeth MacLean, Laura Cisar, Kimberly Mehle, et al.
Future Oncology (London, England)
|
May 10, 2017
Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers
Thomas E Hutson, Xiaolong Jiao, Thomas Wilson, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
July 23, 2017
Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma
Sandy Srinivas, Dara Stein, Dana Y Teltsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2007
Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group
Gilles Vassal, Dominique Couanet, Elizabeth Stockdale, et al.
Journal of the National Cancer Institute
|
October 30, 2012
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer
Arnaud D Roth, Mauro Delorenzi, Sabine Tejpar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2002
Phase I clinical and pharmacologic trial of intravenous estramustine phosphate
Gary Hudes, Naomi Haas, Gwen Yeslow, et al.
Targeted Oncology
|
March 6, 2014
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
Brian I Rini, David I Quinn, Michael Baum, et al.
Targeted Oncology
|
April 1, 2017
Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma
Brian I Rini, Victor Gruenwald, Eric Jonasch, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 25, 2008
A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG)
Gilles Vassal, Francesco Giammarile, Mariel Brooks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2009
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial
Arnaud D Roth, Sabine Tejpar, Mauro Delorenzi, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Journal of Managed Care & Specialty Pharmacy
|
May 28, 2016
Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets
Elizabeth MacLean, Laura Cisar, Kimberly Mehle, et al.
Future Oncology (London, England)
|
May 10, 2017
Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers
Thomas E Hutson, Xiaolong Jiao, Thomas Wilson, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
July 23, 2017
Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma
Sandy Srinivas, Dara Stein, Dana Y Teltsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2007
Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group
Gilles Vassal, Dominique Couanet, Elizabeth Stockdale, et al.
Journal of the National Cancer Institute
|
October 30, 2012
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer
Arnaud D Roth, Mauro Delorenzi, Sabine Tejpar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2002
Phase I clinical and pharmacologic trial of intravenous estramustine phosphate
Gary Hudes, Naomi Haas, Gwen Yeslow, et al.
Targeted Oncology
|
March 6, 2014
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
Brian I Rini, David I Quinn, Michael Baum, et al.
Targeted Oncology
|
April 1, 2017
Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma
Brian I Rini, Victor Gruenwald, Eric Jonasch, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 25, 2008
A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG)
Gilles Vassal, Francesco Giammarile, Mariel Brooks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2009
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial
Arnaud D Roth, Sabine Tejpar, Mauro Delorenzi, et al.
Page
of 2